Estracyt (estramustine) : l’ANSM restreint l’indication thérapeutique et modifie les conditions de prescription et de délivrance (CPD) (ANSM 14 avril 2021)
Powered by
eZ Publish™ CMS Open Source Web Content Management
. Copyright © 1999-2014
eZ Systems AS
(except where otherwise noted). All rights reserved.